S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.45
+1.77
+10.61%
ALXO · ALX Oncology Holdings Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
ALX Oncology Holdings Inc (ALXO)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$1.15
-0.10
(-8.00%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$1.15
$1.15
$1.29
52-WEEK RANGE
$1.15
$0.86
$2.66
What's happening
- ALXO is down 8.00% today, trading at $1.15. — Live quote
- Volume today (42,438) is well below its 3-month average of 1,352,950. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.12 actual vs. $-0.15 estimated (+17.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 8
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (13 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ALXO
+1.77%
vs S&P 500
-11.60%
1-YEAR RETURN
ALXO
-29.88%
vs S&P 500
-45.04%
6-MONTH RETURN
ALXO
-31.14%
3-MONTH RETURN
ALXO
-43.07%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.12
Est. $-0.15
BEAT +17.9%
2026-04-26 (Q1 2026)
$-0.15
Est. $-0.20
BEAT +26.2%
2026-01-26 (Q4 2025)
$-0.37
Est. $-0.37
MISS -0.1%
2025-10-26 (Q3 2025)
$-0.41
Est. $-0.37
MISS -9.6%
Valuation Measures & Ratios
Enterprise Value4$153.3M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)45.15
Price / Book72.05
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin-753.55%
Operating Margin-731.97%
Return on Equity (ROE8)-90.30%
Return on Assets (ROA9)-67.28%
Avg Volume (3M)1,352,950
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $286.2M | $211.4M | $98.0M | $22.1M | $32.9M |
| P/E | -3.41 | -2.18 | -0.89 | -0.17 | -0.24 |
| Price/Book | 2.10 | 1.40 | 2.19 | 0.34 | 0.37 |
| EV/EBITDA | -3.19 | -1.89 | -0.75 | — | — |
| ROE | -61.67% | -63.94% | -244.54% | -196.86% | -154.53% |
| ROA | -52.23% | -54.27% | -132.43% | -133.04% | -112.85% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short5,673,137
Change from Prior Settlement-9.57%
% of Float—
Days to Cover (Short Ratio)3.79
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-15; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -753.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is -29.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ALXO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$18.0M | -$19.0M | -$22.5M | -$26.6M | -$31.8M | -$32.6M | -$41.5M | -$37.8M |
| Net income | -$18.0M | -$17.9M | -$22.1M | -$25.9M | -$30.8M | -$30.7M | -$39.4M | -$35.6M |
| EPS (diluted) | $-0.13 | $-0.17 | $-0.41 | $-0.49 | $-0.58 | $-0.58 | $-0.76 | $-0.71 |
| EPS (basic) | $-0.13 | $-0.17 | $-0.41 | $-0.49 | $-0.58 | $-0.58 | $-0.76 | $-0.71 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $160.8M | $178.3M | $59.0M | $82.7M | $95.3M | $120.9M | $147.8M | $185.7M |
| Total liabilities | $24.6M | $27.0M | $33.1M | $37.9M | $30.9M | $32.6M | $34.2M | $48.9M |
| Stockholders' equity | $136.2M | $151.3M | $26.0M | $44.8M | $64.4M | $88.3M | $113.6M | $136.8M |
| Total current assets | $143.5M | $145.6M | $50.7M | $66.5M | $85.3M | $102.5M | $134.4M | $155.9M |
| Total current liabilities | $14.8M | $20.2M | $24.6M | $27.7M | $18.8M | $18.7M | $18.5M | $32.3M |
| Cash & equivalents | $22.7M | $32.3M | $16.4M | $23.4M | $19.3M | $20.6M | $17.6M | $16.1M |
| Marketable securities (current) | $115.5M | $108.0M | $28.4M | $37.2M | $60.0M | $77.2M | $110.2M | $132.5M |
| Other current assets | $542.0K | $25.0K | $20.0K | — | $4.0K | — | $27.0K | $1.2M |
| Marketable securities (non-current) | $15.1M | $28.8M | $3.5M | $5.8M | $4.2M | $9.2M | $3.5M | $14.0M |
| Property, plant & equipment | $166.0K | $1.1M | $1.2M | $1.4M | $1.5M | $2.7M | $2.9M | $3.1M |
| Other non-current assets | $2.0M | $2.9M | $3.6M | $9.0M | $4.3M | $6.5M | $7.0M | $12.7M |
| Accounts payable | $3.0M | $3.9M | $4.9M | $6.6M | $4.9M | $3.9M | $4.5M | $7.9M |
| Short-term debt | $0 | $5.2M | $5.2M | $4.3M | $3.0M | $1.7M | $435.0K | $0 |
| Other current liabilities | — | — | $0 | $0 | $40.0K | $48.0K | $149.0K | $63.0K |
| Long-term debt | $9.7M | $3.3M | $4.5M | $5.8M | $7.0M | $8.2M | $9.5M | $9.8M |
| Other non-current liabilities | $152.0K | $3.5M | $4.0M | $4.4M | $5.1M | $5.6M | $6.2M | $6.7M |
| Common stock & paid-in capital | $138.0K | $135.0K | $54.0K | $54.0K | $54.0K | $53.0K | $53.0K | $53.0K |
| Retained earnings | -$758.7M | -$740.7M | -$722.8M | -$700.0M | -$677.8M | -$651.9M | -$621.1M | -$592.0M |
| Accumulated other comprehensive income (loss) | -$224.0K | -$245.0K | $28.0K | $43.0K | $36.0K | $118.0K | $275.0K | $563.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.1M | -$18.6M | -$19.0M | -$17.1M | -$23.4M | -$24.7M | -$32.0M | -$25.4M |
| Investing cash flow | $6.5M | -$105.0M | $11.2M | $21.4M | $22.3M | $27.6M | $33.2M | $25.7M |
| Financing cash flow | $137.0K | $139.6M | $678.0K | -$159.0K | -$222.0K | $65.0K | $328.0K | $251.0K |
| Free cash flow | -$16.1M | -$18.7M | -$19.0M | -$17.1M | -$23.5M | -$24.7M | -$32.1M | -$25.5M |
| Capital expenditures | $17.0K | $50.0K | $49.0K | $56.0K | $47.0K | $60.0K | $60.0K | $149.0K |
| Depreciation & amortization | $86.0K | $150.0K | $151.0K | $153.0K | $191.0K | $211.0K | $214.0K | $224.0K |
| Share-based compensation | $2.7M | $2.5M | $2.7M | $2.5M | $2.1M | $5.2M | $5.9M | $7.0M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts payable | -$765.0K | -$1.2M | -$1.7M | $1.7M | $965.0K | -$556.0K | -$3.4M | -$194.0K |
| Purchases of investments | $5.8M | $124.5M | $6.0M | $4.4M | $25.4M | $15.8M | $4.4M | $8.7M |
| Sales/maturities of investments | $12.2M | $19.5M | $17.3M | $25.9M | $47.8M | $43.5M | $37.7M | $34.6M |
| Share repurchases | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 |
| Operating income | -$104.0M | -$142.5M | -$170.3M | -$127.4M | -$83.6M |
| Net income | -$101.7M | -$134.8M | -$160.8M | -$123.5M | -$83.5M |
| EPS (diluted) | $-1.90 | $-2.58 | $-3.74 | $-3.03 | $-2.07 |
| EPS (basic) | $-1.90 | $-2.58 | $-3.74 | $-3.03 | $-2.07 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $59.0M | $147.8M | $242.6M | $306.5M | $380.2M |
| Total liabilities | $33.1M | $34.2M | $52.8M | $43.0M | $17.1M |
| Stockholders' equity | $26.0M | $113.6M | $189.7M | $263.5M | $363.0M |
| Total current assets | $50.7M | $134.4M | $188.7M | $271.0M | $367.0M |
| Total current liabilities | $24.6M | $18.5M | $36.0M | $28.3M | $15.3M |
| Cash & equivalents | $16.4M | $17.6M | $22.4M | $48.8M | $363.7M |
| Marketable securities (current) | $28.4M | $110.2M | $160.3M | $217.4M | — |
| Other current assets | $20.0K | $27.0K | $439.0K | — | — |
| Marketable securities (non-current) | $3.5M | $3.5M | $35.4M | $16.7M | — |
| Property, plant & equipment | $1.2M | $2.9M | $3.6M | $3.9M | $897.0K |
| Other non-current assets | $3.6M | $7.0M | $14.9M | $14.9M | $12.3M |
| Accounts payable | $4.9M | $4.5M | $8.6M | $8.1M | $3.8M |
| Short-term debt | $5.2M | $435.0K | $0 | $0 | — |
| Other current liabilities | $0 | $149.0K | $543.0K | $1.6M | — |
| Long-term debt | $4.5M | $9.5M | $9.6M | $9.4M | — |
| Other non-current liabilities | $4.0M | $6.2M | $7.2M | $5.3M | $1.8M |
| Common stock & paid-in capital | $54.0K | $53.0K | $50.0K | $41.0K | $41.0K |
| Retained earnings | -$722.8M | -$621.1M | -$486.3M | -$325.5M | -$202.0M |
| Accumulated other comprehensive income (loss) | $28.0K | $275.0K | $256.0K | -$845.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$84.1M | -$121.9M | -$130.4M | -$89.2M | -$68.1M |
| Investing cash flow | $82.6M | $86.3M | $44.7M | -$235.4M | -$4.9M |
| Financing cash flow | $362.0K | $30.8M | $59.3M | $9.9M | $2.5M |
| Free cash flow | -$84.4M | -$122.4M | -$131.6M | -$90.7M | -$68.8M |
| Capital expenditures | $212.0K | $447.0K | $1.3M | $1.4M | $666.0K |
| Depreciation & amortization | $706.0K | $872.0K | $836.0K | $342.0K | $51.0K |
| Share-based compensation | $12.6M | $27.1M | $26.3M | $23.8M | $13.9M |
| Deferred income taxes | $0 | $0 | $0 | — | — |
| Change in accounts payable | $421.0K | -$4.0M | $458.0K | $4.5M | $3.3M |
| Purchases of investments | $51.6M | $107.4M | $246.6M | $376.8M | — |
| Sales/maturities of investments | $134.4M | $194.1M | $292.6M | $142.8M | — |
| Share repurchases | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ALXO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-01-06 to 2026-08-17
Recent transactions
- Insiders have net sold 4,207 shares over the last 182 days, across 0 purchases and 3 sales.
- Most recent: Lettmann Jason (CHIEF EXECUTIVE OFFICER) — Open market sale of 2,230 shares on 2026-08-17.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)4,207 sh(3 txns)
Net Shares-4,207
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Lettmann Jason | CHIEF EXECUTIVE OFFICER | Open market sale | 2026-08-17 | 2,230 |
| Wong Shelly | SVP, FINANCE AND CAO | Open market sale | 2026-08-17 | 573 |
| Pinto Shelly | SVP, FINANCE AND CAO | Open market sale | 2026-03-19 | 903 |
| GOODMAN COREY S | Reporting person | Open market purchase | 2026-02-02 | 3,184,713 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-17 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Open market sale | 2,230 | $1.93 |
| 2026-08-17 | Wong Shelly | SVP, FINANCE AND CAO | Open market sale | 573 | $1.93 |
| 2026-07-01 | Wong Shelly | SVP, FINANCE AND CAO | Open market sale | 1,404 | $2.04 |
| 2026-03-19 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Open market sale | 12,311 | $2.17 |
| 2026-03-19 | Pinto Shelly | SVP, FINANCE AND CAO | Open market sale | 903 | $2.17 |
| 2026-02-18 | Pinto Shelly | SVP, FINANCE AND CAO | Open market sale | 565 | $2.27 |
| 2026-02-17 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Tax withholding | 2,201 | $2.27 |
| 2026-02-02 | GOODMAN COREY S | Reporting person | Open market purchase | 3,184,713 | $1.57 |
| 2026-01-06 | Pinto Shelly | SVP, FINANCE AND CAO | Open market sale | 3,925 | $1.11 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:31 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-15 | 8-K | 2026-10-14 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-06 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-06-30 | 8-K | 2026-06-29 | View on SEC.gov → |
| 2026-06-26 | 8-K | 2026-06-25 | View on SEC.gov → |
| 2026-06-11 | 8-K | 2026-06-10 | View on SEC.gov → |
| 2026-05-08 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-08 | 8-K | 2026-05-08 | View on SEC.gov → |
| 2026-04-17 | 4 | 2026-04-16 | View on SEC.gov → |
Recent news
Headlines about ALXO (ALX Oncology Holdings Inc.). Links open the publisher — we don’t host full articles.
-
Form 13D/A ALX ONCOLOGY HOLDINGS INC For: 16 October By Investing.com
Investing.com India · 2026-10-17 -
A $0.001-per-share warrant is at the center of ALX Oncology (ALXO)'s agreed share exchange.
Stock Titan · 2026-10-17 -
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 2026-10-16 -
ALXO261120C00002000 Interactive Stock Chart | ALXO Nov 2026 2.000 call Stock - Yahoo Finance
Yahoo! Finance Canada · 2026-10-16 -
ALXO Nov 2026 2.000 call (ALXO261120C00002000) Interactive Stock Chart - Yahoo Finance
Yahoo! Finance Canada · 2026-10-16 -
ALXO Nov 2026 2.000 call (ALXO261120C00002000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-16 -
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
Yahoo Finance · 2026-09-28 -
ALX Oncology to Present at Upcoming Investor Conferences in September
Yahoo Finance · 2026-09-02
No headlines in this category right now — try “All”.